MedTrace Logo

Early Detection of Prostate Cancer by FACS

NCT00524823 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2007-09-05

No results posted yet for this study

Summary

Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.

Conditions

Sponsors & Collaborators

  • Ziv Hospital

    lead OTHER_GOV

Principal Investigators

  • Nina Kucherski, MD · Ziv Medical Center

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524823 on ClinicalTrials.gov